January 21, 2026
AMH Testing: Revolutionizing Fertility Treatment Accuracy
Anti-Müllerian hormone (AMH) testing is now a standard in fertility care, offering precise predictions of ovarian reserve and treatment outcomes. Studies confirm AMH levels correlate with follicle count, guiding personalized protocols. At Shady Grove Fertility, 90% of patients with insurance cover the $70–$139 test, which helps tailor IVF dosing and identify risks like menopause timing.
Key Takeaways
AMH Blood Test: Reliable Ovarian Reserve Predictor
AMH levels, measured via a simple blood test at any menstrual cycle phase, directly reflect follicle pool size. High AMH indicates abundant eggs, while low levels signal diminished reserve. This test is superior to FSH in detecting early ovarian decline.
AMH-Guided Fertility Protocols for Personalized Care
Physicians use AMH results to adjust stimulation medication doses. High AMH patients may risk over-response, requiring tailored protocols, while low AMH patients need optimized strategies to maximize egg retrieval and pregnancy success.
AMH Testing During Contraceptive Use: Key Considerations
Continuous combined contraceptives (pills, patches) lower AMH readings. Women on birth control with low results should retest after one month off hormones for accurate baseline assessment.
AMH and PCOS Correlation: Diagnosing Severity
Women with PCOS exhibit elevated AMH due to excess antral follicles. Levels correlate with insulin resistance severity, aiding in diagnosis and treatment planning for this common fertility condition.
AMH as Early Menopause Predictor: Research Advances
Emerging studies link AMH levels to menopause timing. Lower AMH indicates earlier menopause risk, prompting proactive family planning decisions. SGF integrates this data into patient evaluations for comprehensive care.
Source: Read full article